[Capital Cube] Alere Inc (NYSE:ALR)(TREND ANALYSIS) change in share price of 29.97% for the last 12 months is better than its peer median. However, the 30-day trend in its share price performance of -2.65% is now around the peer median suggesting that the company’s recent performance has faded relative to peers.
Stock Performance: Click here for a free comprehensive Trend Analysis Report
Alere Inc (NYSE:ALR) stock is currently trading 12.48% below its 52-week-high, 37.56% above its 52-week-low. The 1-year stock price history is in the range of $35.62 – $55.99. AlereInc (ALR) has a price to earnings ratio of 18.67 versus Healthcare sector average of 54.18. ALR stock price has outperformed the S&P 500 by 33.8%. The Diagnostic Kits company is currently valued at $4.2 billion and its share price closed the last trading session at $49. The stock has a 50-day moving average of $52.51 and a 200-day moving average of $50.83.
AlereInc (ALR) current short interest stands at 3.21 million shares. It has increased by 8% from the same period of last month. Around 5% of the company’s shares, which are float, are short sold. With a 10-days average volume of 0.53 million shares, the number of days required to cover the short positions stand at 6.1 days.
The company is expected to announce next quarter earnings on October 27, at consensus estimate of $0.55. AlereInc (ALR) reported last quarter earnings on August 04. The Diagnostic Kits company announced earnings per share of $0.49 against a consensus Street estimate of $0.53, missing estimate by $0.04. This corresponds to an increase of $0.1 compared to the same quarter of the previous fiscal year.
Is this a Buying Opportunity? Click here for a free Trend Analysis Report
There are currently nine analysts that cover AlereInc stock. Of those nine, six have a Buy rating, three have a Hold rating. On a consensus basis this yields to an Overweight rating. The consensus target price stands at $56.78.
A recent analyst activity consisted of Goldman Sachs upgrading their Neutral rating to Buy on June 23. Goldman Sachs increased their price target on ALR from $50 to $60. This corresponds to a 22.45% upside from the last closing price. On the date of report, the stock closed at $52.04.
CanaccordGenuity reiterated their Buy stance on April 7, and increased their price target on ALR stock from $50 to $56. This corresponds to a 14.29% upside from the last closing price. On the date of report, the stock closed at $50.12.
AlereInc (ALR) has a debt to equity ratio of 195% compared to Healthcare sector average of 62.2%. The company has a current ratio of 1.7. This ratio should be higher than one (ideally two) and is an indicator to show if the company is able to finance its short term obligations. Indeed it should have higher short term assets to dispose in order to cover for its short term liabilities.
Alere, Inc. offers patient diagnosis, monitoring and health management services. The Company produces consumer and professional medical diagnostic products, and remotely monitors patients for pre-eclampsia, and patients who are prescribed Warfarin for atrial fibrillation.